Masimo Corporation $MASI Holdings Trimmed by Baird Financial Group Inc.

Baird Financial Group Inc. trimmed its position in shares of Masimo Corporation (NASDAQ:MASI) by 9.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,720 shares of the medical equipment provider’s stock after selling 4,400 shares during the period. Baird Financial Group Inc. owned about 0.07% of Masimo worth $6,850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in MASI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Masimo by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after acquiring an additional 66 shares in the last quarter. Assetmark Inc. raised its stake in Masimo by 5.0% during the 2nd quarter. Assetmark Inc. now owns 1,539 shares of the medical equipment provider’s stock valued at $259,000 after purchasing an additional 73 shares during the last quarter. Deutsche Bank AG boosted its holdings in Masimo by 1.5% in the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after purchasing an additional 92 shares during the period. ProShare Advisors LLC boosted its holdings in Masimo by 5.3% in the 2nd quarter. ProShare Advisors LLC now owns 1,995 shares of the medical equipment provider’s stock valued at $336,000 after purchasing an additional 101 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Masimo by 2.9% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,039 shares of the medical equipment provider’s stock worth $673,000 after purchasing an additional 115 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MASI shares. Bank of America initiated coverage on Masimo in a report on Monday, November 17th. They issued a “neutral” rating and a $162.00 price target for the company. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Monday, December 1st. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $190.00 price objective on shares of Masimo in a report on Friday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Masimo currently has a consensus rating of “Hold” and a consensus price target of $189.40.

Masimo Stock Performance

NASDAQ MASI opened at $140.85 on Tuesday. Masimo Corporation has a 1-year low of $133.70 and a 1-year high of $194.88. The company has a 50 day moving average of $145.81 and a 200-day moving average of $151.80. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69. The firm has a market cap of $7.57 billion, a price-to-earnings ratio of -13.36, a PEG ratio of 1.54 and a beta of 1.26.

Masimo (NASDAQ:MASI) last announced its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The business had revenue of $617.00 million for the quarter. On average, equities analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.